IL242331B - Preparation of Amorphous Taquirimate - Google Patents

Preparation of Amorphous Taquirimate

Info

Publication number
IL242331B
IL242331B IL242331A IL24233115A IL242331B IL 242331 B IL242331 B IL 242331B IL 242331 A IL242331 A IL 242331A IL 24233115 A IL24233115 A IL 24233115A IL 242331 B IL242331 B IL 242331B
Authority
IL
Israel
Prior art keywords
tecovirimat
amorphous
preparation
tecovirimat preparation
amorphous tecovirimat
Prior art date
Application number
IL242331A
Other languages
English (en)
Hebrew (he)
Original Assignee
Siga Tech
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Siga Tech filed Critical Siga Tech
Publication of IL242331B publication Critical patent/IL242331B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/4035—Isoindoles, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/58—[b]- or [c]-condensed
    • C07D209/70—[b]- or [c]-condensed containing carbocyclic rings other than six-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/58—[b]- or [c]-condensed
    • C07D209/72—4,7-Endo-alkylene-iso-indoles
    • C07D209/76—4,7-Endo-alkylene-iso-indoles with oxygen atoms in positions 1 and 3

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Inorganic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL242331A 2013-07-19 2015-10-29 Preparation of Amorphous Taquirimate IL242331B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361856240P 2013-07-19 2013-07-19
PCT/US2014/046340 WO2015009566A1 (en) 2013-07-19 2014-07-11 Amorphous tecovirimat preparation

Publications (1)

Publication Number Publication Date
IL242331B true IL242331B (en) 2021-02-28

Family

ID=52346653

Family Applications (1)

Application Number Title Priority Date Filing Date
IL242331A IL242331B (en) 2013-07-19 2015-10-29 Preparation of Amorphous Taquirimate

Country Status (8)

Country Link
US (3) US9670158B2 (enExample)
EP (2) EP3763702B1 (enExample)
JP (3) JP6843616B2 (enExample)
CN (2) CN105307636A (enExample)
AU (1) AU2014290333B2 (enExample)
CA (3) CA2917199C (enExample)
IL (1) IL242331B (enExample)
WO (1) WO2015009566A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105307636A (zh) * 2013-07-19 2016-02-03 西佳技术公司 非晶形特考韦瑞制备
CN107126419B (zh) * 2016-02-26 2020-06-19 石药集团中诺药业(石家庄)有限公司 一种奥贝胆酸片剂及其制备方法
CN112955130A (zh) * 2018-10-30 2021-06-11 佩洛通治疗公司 包含取代茚满的固体分散体和药物组合物及其制备和使用方法
CN115141136B (zh) * 2021-03-31 2023-06-20 中国人民解放军军事科学院军事医学研究院 特考韦瑞药的共晶及其制备方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20011184A1 (es) 2000-03-16 2001-11-15 Pfizer Prod Inc Composiciones farmaceuticas de inhibidores de la glucogeno-fosforilasa
US6596771B2 (en) 2001-01-12 2003-07-22 Schering Corporation Drugs for treating viral infections
US6433016B1 (en) 2001-01-12 2002-08-13 Vassil Stefanov Georgiev Drugs for treating viral infections
US7687641B2 (en) 2003-06-20 2010-03-30 Siga Technologies, Inc. Chemicals, compositions, and methods for treatment and prevention of orthopoxvirus infections and associated diseases
PL1638938T3 (pl) 2003-06-20 2017-10-31 Siga Tech Inc Związki, kompozycje i sposoby do leczenia i zapobiegania infekcjom ortopokswirusami i powiązanym chorobom
WO2006110655A2 (en) * 2005-04-08 2006-10-19 Chimerix, Inc. Compounds, compositions and methods for the treatment of poxvirus infections
JP2010526848A (ja) * 2007-05-11 2010-08-05 エフ.ホフマン−ラ ロシュ アーゲー 難溶性薬物用の医薬組成物
PE20170944A1 (es) * 2010-03-23 2017-07-13 Siga Tech Inc Formas polimorficas de st-246 y metodos de preparacion
RU2566716C2 (ru) * 2010-06-09 2015-10-27 Эббви Бахамаз Лтд. Твердые дисперсии, содержащие ингибиторы киназ
GB201103837D0 (en) * 2011-03-07 2011-04-20 Oxagen Ltd Amorphous (5-Fluoro-2-Methyl-3-Quinolin-2-Ylmethyl-Indol-1-Yl)-acetic acid
WO2012122279A1 (en) * 2011-03-08 2012-09-13 Zalicus Pharmaceuticals Ltd. Solid dispersion formulations and methods of use thereof
KR102000312B1 (ko) * 2011-10-14 2019-07-15 어레이 바이오파마 인크. Erb2 (her2) 저해제의 고체 분산물
JP2013103899A (ja) * 2011-11-11 2013-05-30 Fuji Chem Ind Co Ltd 難溶性薬物の新規な固体分散体
CN102406617B (zh) * 2011-11-30 2013-08-28 中国人民解放军军事医学科学院生物工程研究所 一种替韦立马干混悬剂及其制备方法
CN105307636A (zh) 2013-07-19 2016-02-03 西佳技术公司 非晶形特考韦瑞制备

Also Published As

Publication number Publication date
CA3246369A1 (en) 2025-10-30
EP3763702A1 (en) 2021-01-13
US9670158B2 (en) 2017-06-06
EP3021836A4 (en) 2016-12-07
CA2917199C (en) 2021-08-31
CA2917199A1 (en) 2015-01-22
EP3021836A1 (en) 2016-05-25
WO2015009566A1 (en) 2015-01-22
JP2016527229A (ja) 2016-09-08
JP2023080234A (ja) 2023-06-08
JP2021028336A (ja) 2021-02-25
US10045963B2 (en) 2018-08-14
US20160152565A1 (en) 2016-06-02
CN105307636A (zh) 2016-02-03
AU2014290333B2 (en) 2018-11-08
US20170224661A1 (en) 2017-08-10
WO2015009566A8 (en) 2015-12-10
JP6843616B2 (ja) 2021-03-17
JP7681393B2 (ja) 2025-05-22
EP3763702B1 (en) 2023-12-13
US20180125819A1 (en) 2018-05-10
EP3021836B1 (en) 2020-10-07
AU2014290333A1 (en) 2015-12-03
CN111635353A (zh) 2020-09-08
CA3128535C (en) 2024-10-15
US9889119B2 (en) 2018-02-13
CA3128535A1 (en) 2015-01-22

Similar Documents

Publication Publication Date Title
DK3689865T3 (en) Hidtil ukendte aminopyrimidinderivater
DK3088517T5 (en) Humant anti-il-33-neutraliserende monoklonalt antistof
DK3736291T3 (en) Anti-FCRH5-antistoffer
DK3354246T3 (en) Udstyrsmonteringssystem
DK3077519T3 (en) Cmv-vacciner
DK3470074T3 (en) Probiotika
AU353575S (en) Stamphousing
GB201301329D0 (en) Fluidfoil
CA3246369A1 (en) Amorphous tecovirimat preparation
DK2979701T3 (en) Antitumormiddel indbefattende irinotecanhydrochloridhydrat
EP3014557A4 (en) TELEPHONE ON FILE
GB201300903D0 (en) Crystalline Form
GB201300001D0 (en) Envirep - environment replicater
DK2989854T3 (en) Strømstyret opvarmningssystem
AU4899P (en) Herbie53 Iresine herbstii
AU4953P (en) Flogazora Gazania rigens
AU4977P (en) Harrosy Gaura lindheimeri
GB201310280D0 (en) Odontalgic preparation
AU353330S (en) Kettlebell
AU353327S (en) Kettlebell
AU353326S (en) Kettlebell
AU353328S (en) Kettlebell
AU353329S (en) Kettlebell
GB201302952D0 (en) Easily fitted longerie
AP00812S1 (en) Stumbelbloc

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed